% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gouttefangeas:277351,
      author       = {C. Gouttefangeas$^*$ and R. Klein and A. Maia},
      title        = {{T}he good and the bad of {T} cell cross-reactivity:
                      challenges and opportunities for novel therapeutics in
                      autoimmunity and cancer.},
      journal      = {Frontiers in immunology},
      volume       = {14},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-01357},
      pages        = {1212546},
      year         = {2023},
      abstract     = {T cells are main actors of the immune system with an
                      essential role in protection against pathogens and cancer.
                      The molecular key event involved in this absolutely central
                      task is the interaction of membrane-bound specific T cell
                      receptors with peptide-MHC complexes which initiates T cell
                      priming, activation and recall, and thus controls a range of
                      downstream functions. While textbooks teach us that the
                      repertoire of mature T cells is highly diverse, it is clear
                      that this diversity cannot possibly cover all potential
                      foreign peptides that might be encountered during life. TCR
                      cross-reactivity, i.e. the ability of a single TCR to
                      recognise different peptides, offers the best solution to
                      this biological challenge. Reports have shown that indeed,
                      TCR cross-reactivity is surprisingly high. Hence, the T cell
                      dilemma is the following: be as specific as possible to
                      target foreign danger and spare self, while being able to
                      react to a large spectrum of body-threatening situations.
                      This has major consequences for both autoimmune diseases and
                      cancer, and significant implications for the development of
                      T cell-based therapies. In this review, we will present
                      essential experimental evidence of T cell cross-reactivity,
                      implications for two opposite immune conditions, i.e.
                      autoimmunity vs cancer, and how this can be differently
                      exploited for immunotherapy approaches. Finally, we will
                      discuss the tools available for predicting cross-reactivity
                      and how improvements in this field might boost translational
                      approaches.},
      subtyp        = {Review Article},
      keywords     = {T cell receptor (Other) / autoimmunity (Other) / cancer
                      (Other) / cross-reactivity (Other) / immunotherapy (Other)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37409132},
      pmc          = {pmc:PMC10319254},
      doi          = {10.3389/fimmu.2023.1212546},
      url          = {https://inrepo02.dkfz.de/record/277351},
}